文献速递新生儿儿童感染

快速床旁基因分型避免新生儿重症监护中氨基糖苷类耳毒性

Rapid Point-of-Care Genotyping to Avoid Aminoglycoside-Induced Ototoxicity in Neonatal Intensive Care.
PubMed 文献 · JAMA Pediatr · 2022-01-01

这项在英国两个大型新生儿重症监护室开展的实用性前瞻性实施试验,纳入751名新生儿,评估快速床旁检测(POCT)MT-RNR1 m.1555A>G变异以指导抗生素处方并避免氨基糖苷类诱导耳毒性(AIO)的可行性。结果显示POCT在26分钟内完成基因分型,临床前验证灵敏度100%(95%CI 93.9%-100.0%)、特异度100%(95%CI 98.5%-100.0%),80.6%接受抗生素的婴儿成功检测,3名携带变异者均避免使用氨基糖苷类,且抗生素给药时间与既往实践相当。

要点

  • POCT可在26分钟内检测MT-RNR1 m.1555A>G变异,临床前验证灵敏度和特异度均为100%。
  • 80.6%接受抗生素的婴儿成功完成检测,3名携带变异者均避免使用氨基糖苷类。
  • 实施POCT未干扰常规临床实践,抗生素给药时间与既往相当。

核心结论

  • MT-RNR1 POCT可整合入临床实践而不干扰常规流程,并利用基因型指导抗生素处方以避免AIO。
  • 该方法在可改变实践的时间窗内识别m.1555A>G变异,广泛采用可能显著减轻AIO负担。

研究设计与样本

  • 共纳入751名新生儿,中位(范围)年龄2.5(0-198)天,入院时通过快速POCT检测m.1555A>G变异。

主要发现

  • MT-RNR1 POCT能在26分钟内对m.1555A>G变异进行基因分型。
  • 临床前验证显示100%灵敏度(95%CI,93.9%-100.0%)和100%特异度(95%CI,98.5%-100.0%)。
  • 鉴定出3名m.1555A>G变异携带者,均避免了氨基糖苷类抗生素。
  • 424名(80.6%)接受抗生素的婴儿成功检测了该变异,抗生素平均给药时间与既往实践相当。

临床怎么用

  • 在新生儿重症监护室入院时对新生儿进行MT-RNR1 m.1555A>G变异快速POCT检测,以指导抗生素处方。
  • 对检测出m.1555A>G变异的新生儿避免使用氨基糖苷类抗生素,以预防AIO。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Aminoglycosides are commonly prescribed antibiotics used for the treatment of neonatal sepsis. The MT-RNR1 m.1555A>G variant predisposes to profound aminoglycoside-induced ototoxicity (AIO). Current genotyping approaches take several days, which is unfeasible in acute settings. OBJECTIVE: To develop a rapid point-of-care test (POCT) for the m.1555A>G variant before implementation of this technology in the acute neonatal setting to guide antibiotic prescribing and avoid AIO. DESIGN, SETTING, AND PARTICIPANTS: This pragmatic prospective implementation trial recruited neonates admitted to 2 large neonatal intensive care units between January 6, 2020, and November 30, 2020, in the UK. INTERVENTIONS: Neonates were tested for the m.1555A>G variant via the rapid POCT on admission to the neonatal intensive care unit. MAIN OUTCOMES AND MEASURES: The primary outcome assessed the proportion of neonates successfully tested for the variant of all infants prescribed antibiotics. Secondary outcomes measured whether implementation was negatively associated with routine clinical practice and the performance of the system. The study was statistically powered to detect a significant difference between time to antibiotic administration before and after implementation of the MT-RNR1 POCT. RESULTS: A total of 751 neonates were recruited and had a median (range) age of 2.5 (0-198) days. The MT-RNR1 POCT was able to genotype the m.1555A>G variant in 26 minutes. Preclinical validation demonstrated a 100% sensitivity (95% CI, 93.9%-100.0%) and specificity (95% CI, 98.5%-100.0%). Three participants with the m.1555A>G variant were identified, all of whom avoided aminoglycoside antibiotics. Overall, 424 infants (80.6%) receiving antibiotics were successfully tested for the variant, and the mean time to antibiotics was equivalent to previous practice. CONCLUSIONS AND RELEVANCE: The MT-RNR1 POCT was integrated without disrupting normal clinical practice, and genotype was used to guide antibiotic prescription and avoid AIO. This approach identified the m.1555A>G variant in a practice-changing time frame, and wide adoption could significantly reduce the burden of AIO.

来源:JAMA Pediatr,查看原文。版权归原作者所有。

引用

  1. McDermott JH, Mahaveer A, James RA, et al. Rapid Point-of-Care Genotyping to Avoid Aminoglycoside-Induced Ototoxicity in Neonatal Intensive Care. JAMA Pediatr. 2022. PMID: 35311942. doi:10.1001/jamapediatrics.2022.0187

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。